This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What are the primary methods used for bioconjugation in antibody drug-conjugate (ADC) development, and how do they influence the stability and efficacy of the resulting ADCs? Site-specific conjugation methods are primarily utilised for a significant portion of ADCs in clinicaldevelopments.
He continued his education at Indiana University, where he completed a Master of Arts in botany in 1964, and a Doctor of Philosophy in organicchemistry in 1965. He attributes his success to good fortune and hard work, and hopes to see some of his patented compounds gain approval and reach market readiness in the coming years.
He focused on corporate and business unit strategies, organizational transformations, product launches, growth strategies and new market entries. Previously, Baffa was Therapeutic Area Head of Oncology, Global ClinicalDevelopment for Shire. Additionally, Raffaele Baffa was named chief medical officer of Ziopharm.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Clinical Development 
75 
Let's personalize your content